Pharsight

1. Adrenalin patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10653646	ENDO OPERATIONS	Epinephrine compositions and containers	Mar, 2039 (14 years from now)
US11207280	ENDO OPERATIONS	Epinephrine compositions and containers	Mar, 2039 (14 years from now)
US11083698	ENDO OPERATIONS	Epinephrine compositions and containers	Mar, 2039 (14 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 21 April, 2023

Treatment: To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock

Dosage: SOLUTION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg/mL ampules	09 Mar, 2016	1	06 Jul, 2018	13 Mar, 2035	Deferred
30 mg/30 mL	20 Aug, 2018	1	24 Apr, 2020	13 Mar, 2035	Eligible

Strength	Dosage	Availability
10MG/250ML (40MCG/ML)	SOLUTION	Prescription
2MG/250ML (8MCG/ML)	SOLUTION	Prescription
4MG/250ML (16MCG/ML)	SOLUTION	Prescription
8MG/250ML (32MCG/ML)	SOLUTION	Prescription
5MG/250ML (20MCG/ML)	SOLUTION	Prescription

ADRENALIN family patents

2. Airduo Digihaler patent expiration

Application	Filing Date	Opposition Party	Legal Status

EP17800844A	2020-06-03	Vectura Limited	Opposition rejected
EP17800844A	2020-02-14	CHIESI FARMACEUTICI S.p.A.	Opposition rejected

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000653 (Pediatric)	TEVA PHARM	Inhaler	Jun, 2039 (14 years from now)
US11969544	TEVA PHARM	Inhalers and airflow adaptors therefor	Aug, 2039 (14 years from now)
US11344685	TEVA PHARM	Drug delivery device with electronics	Sep, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-61)	Jul 09, 2024
Pediatric Exclusivity(PED)	Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER

Strength	Dosage	Availability
0.055MG/INH;EQ 0.014MG BASE/INH	POWDER	Discontinued
0.113MG/INH;EQ 0.014MG BASE/INH	POWDER	Discontinued
0.232MG/INH;EQ 0.014MG BASE/INH	POWDER	Discontinued

AIRDUO DIGIHALER family patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Airduo Respiclick patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11969544	TEVA PHARM	Inhalers and airflow adaptors therefor	Aug, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jan 27, 2020
M(M-61)	Jul 09, 2024
Pediatric Exclusivity(PED)	Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER

Strength	Dosage	Availability
0.232MG/INH;EQ 0.014MG BASE/INH	POWDER	Prescription
0.113MG/INH;EQ 0.014MG BASE/INH	POWDER	Prescription
0.055MG/INH;EQ 0.014MG BASE/INH	POWDER	Prescription

AIRDUO RESPICLICK family patents

4. Angiomax Rtu patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11918622	MAIA PHARMS INC	Ready-to-use bivalirudin compositions	May, 2039 (14 years from now)
US11992514	MAIA PHARMS INC	Ready-to-use bivalirudin compositions	May, 2039 (14 years from now)
US11903993	MAIA PHARMS INC	Ready-to-use bivalirudin compositions	May, 2039 (14 years from now)

Drugs and Companies using BIVALIRUDIN ingredient

Market Authorisation Date: 25 July, 2019

Treatment: Use as an anticoagulant in patients undergoing percutaneous coronary intervention (pci)

Dosage: SOLUTION

Strength	Dosage	Availability
250MG/50ML (5MG/ML)	SOLUTION	Prescription

ANGIOMAX RTU family patents

5. Anjeso patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458145	BAUDAX	Methods of administering intravenous meloxicam in a bolus dose	Mar, 2039 (14 years from now)
US10881663	BAUDAX	Method of treating pain in elderly patients with mild renal impairment	Mar, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Feb 20, 2023

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 20 February, 2020

Treatment: Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection in patients with mild renal impairment

Dosage: SOLUTION

Strength	Dosage	Availability
30MG/ML (30MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SOLUTION	Discontinued

ANJESO family patents

6. Annovera patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10780047	MAYNE PHARMA	Method of providing birth control	Feb, 2039 (14 years from now)
US10765628	MAYNE PHARMA	Method of providing birth control	Feb, 2039 (14 years from now)
US10632066	MAYNE PHARMA	Method of providing birth control	Feb, 2039 (14 years from now)
US10918649	MAYNE PHARMA	System for providing birth control	Jun, 2039 (14 years from now)
US11529308	MAYNE PHARMA	System for providing birth control	Jun, 2039 (14 years from now)
US11850251	MAYNE PHARMA	System for providing birth control	Jun, 2039 (14 years from now)
US10925882	MAYNE PHARMA	System for providing birth control	Jun, 2039 (14 years from now)
US10940157	MAYNE PHARMA	System for providing birth control	Jun, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 10, 2023

Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: Method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles; Method of...

Dosage: RING

Strength	Dosage	Availability
0.013MG/24HR;0.15MG/24HR	RING	Prescription

ANNOVERA family patents

7. Aristada patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273158	ALKERMES INC	Aripiprazole dosing strategy	Apr, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 05, 2020

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

NCE-1 date: 06 October, 2019

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE

Strength	Dosage	Availability
441MG/1.6ML (275.63MG/ML)	SUSPENSION, EXTENDED RELEASE	Prescription
662MG/2.4ML (275.83MG/ML)	SUSPENSION, EXTENDED RELEASE	Prescription
882MG/3.2ML (275.63MG/ML)	SUSPENSION, EXTENDED RELEASE	Prescription
1064MG/3.9ML (272.82MG/ML)	SUSPENSION, EXTENDED RELEASE	Prescription

ARISTADA family patents

8. Aristada Initio Kit patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273158	ALKERMES INC	Aripiprazole dosing strategy	Apr, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 05, 2020

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

NCE-1 date: 06 October, 2019

Market Authorisation Date: 29 June, 2018

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE

Strength	Dosage	Availability
675MG/2.4ML (281.25MG/ML)	SUSPENSION, EXTENDED RELEASE	Prescription

ARISTADA INITIO KIT family patents

9. Armonair Digihaler patent expiration

Application	Filing Date	Opposition Party	Legal Status

EP17800844A	2020-06-03	Vectura Limited	Opposition rejected
EP17800844A	2020-02-14	CHIESI FARMACEUTICI S.p.A.	Opposition rejected

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11357935 (Pediatric)	TEVA PHARM	Drug delivery device with electronics	Mar, 2039 (14 years from now)
US11000653 (Pediatric)	TEVA PHARM	Inhaler	Jun, 2039 (14 years from now)
US11969544	TEVA PHARM	Inhalers and airflow adaptors therefor	Aug, 2039 (14 years from now)
US11344685	TEVA PHARM	Drug delivery device with electronics	Sep, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jul 09, 2024
Pediatric Exclusivity(PED)	Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER

Strength	Dosage	Availability
0.232MG/INH	POWDER	Discontinued
0.03MG/INH	POWDER	Discontinued
0.113MG/INH	POWDER	Discontinued
0.055MG/INH	POWDER	Discontinued

ARMONAIR DIGIHALER family patents

10. Armonair Respiclick patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11969544	TEVA PHARM	Inhalers and airflow adaptors therefor	Aug, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jan 27, 2020
New Patient Population(NPP)	Jul 09, 2024
New Strength(NS)	Jul 09, 2024
Pediatric Exclusivity(PED)	Jan 09, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER

Strength	Dosage	Availability
0.055MG/INH	POWDER	Discontinued
0.232MG/INH	POWDER	Discontinued
0.03MG/INH	POWDER	Discontinued
0.113MG/INH	POWDER	Discontinued

ARMONAIR RESPICLICK family patents

11. Baqsimi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10765602	AMPHASTAR PHARMS INC	Medication delivery systems and methods	Sep, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jul 24, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 24 July, 2019

Treatment: NA

Dosage: POWDER

Strength	Dosage	Availability
3MG	POWDER	Prescription

BAQSIMI family patents

12. Brexafemme patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11534433	SCYNEXIS	Antifungal agents with enhanced activity in acidic pH	Jun, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-903)	Nov 30, 2025
New Chemical Entity Exclusivity(NCE)	Jun 01, 2026
Generating Antibiotic Incentives Now(GAIN)	Jun 01, 2031

Drugs and Companies using IBREXAFUNGERP CITRATE ingredient

NCE-1 date: 01 June, 2030

Market Authorisation Date: 01 June, 2021

Treatment: Reduction in the incidence of recurrent vulvovaginal candidiasis (rvvc) in adult and post-menarchal pediatric females

Dosage: TABLET

Strength	Dosage	Availability
EQ 150MG BASE	TABLET	Prescription

BREXAFEMME family patents

13. Brukinsa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11701357	BEIGENE	Treatment of B cell cancers using a combination comprising Btk inhibitors	Jun, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-871)	Aug 31, 2024
New Indication(I-874)	Sep 14, 2024
New Chemical Entity Exclusivity(NCE)	Nov 14, 2024
New Indication(I-817)	Jan 19, 2026
Orphan Drug Exclusivity(ODE-276)	Nov 14, 2026
New Indication(I-936)	Mar 07, 2027
Orphan Drug Exclusivity(ODE-371)	Aug 31, 2028
Orphan Drug Exclusivity(ODE-370)	Sep 14, 2028
Orphan Drug Exclusivity(ODE-274)	Jan 19, 2030
Orphan Drug Exclusivity(ODE-467)	Mar 07, 2031

Drugs and Companies using ZANUBRUTINIB ingredient

NCE-1 date: 15 November, 2023

Market Authorisation Date: 14 November, 2019

Treatment: Treatment of adult patients with relapsed or refractory follicular lymphoma (fl), in combination with obinutuzumab, after two or more lines of systemic therapy

Dosage: CAPSULE

Strength	Dosage	Availability
80MG	CAPSULE	Prescription

BRUKINSA family patents

14. Bylvay patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10975046	IPSEN	Crystal modifications of odevixibat	Jun, 2039 (14 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11802115	IPSEN	Pharmaceutical formulation of odevixibat	Jun, 2039 (14 years from now)
US11801226	IPSEN	Pharmaceutical formulation of odevixibat	Jun, 2039 (14 years from now)
US11365182	IPSEN	Crystal modifications of odevixibat	Jun, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-918)	Jun 13, 2026
New Chemical Entity Exclusivity(NCE)	Jul 20, 2026
Orphan Drug Exclusivity(ODE-363)	Jul 20, 2028
Orphan Drug Exclusivity(ODE-436)	Jun 13, 2030

Drugs and Companies using ODEVIXIBAT ingredient

NCE-1 date: 20 July, 2025

Market Authorisation Date: 20 July, 2021

Treatment: Method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic)

Dosage: CAPSULE; CAPSULE, PELLETS

Strength	Dosage	Availability
0.4MG	CAPSULE	Prescription
0.2MG	CAPSULE, PELLETS	Prescription
1.2MG	CAPSULE	Prescription
0.6MG	CAPSULE, PELLETS	Prescription

BYLVAY family patents

15. Camcevi Kit patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11717555	ACCORD	Pharmaceutical compositions having a selected release duration	Jan, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 25, 2024

Drugs and Companies using LEUPROLIDE MESYLATE ingredient

Market Authorisation Date: 25 May, 2021

Treatment: NA

Dosage: EMULSION

Strength	Dosage	Availability
EQ 42MG BASE	EMULSION	Prescription

CAMCEVI KIT family patents

16. Caplyta patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11052084	INTRA-CELLULAR	Pharmaceutical capsule compositions comprising lumateperone mono-tosylate	Aug, 2039 (14 years from now)
US11690842	INTRA-CELLULAR	Pharmaceutical capsule compositions comprising lumateperone mono-tosylate	Aug, 2039 (14 years from now)
US10695345	INTRA-CELLULAR	Pharmaceutical capsule compositions comprising lumateperone mono-tosylate	Aug, 2039 (14 years from now)
US11806348	INTRA-CELLULAR	Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate	Aug, 2039 (14 years from now)
US12070459	INTRA-CELLULAR	Pharmaceutical capsule compositions comprising lumateperone mono-tosylate	Aug, 2039 (14 years from now)
US11980617	INTRA-CELLULAR	Methods of treating acute depression and/or acute anxiety	Oct, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-882)	Dec 17, 2024
New Chemical Entity Exclusivity(NCE)	Dec 20, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 21 December, 2023

Market Authorisation Date: 22 April, 2022

Treatment: Treatment of schizophrenia mediated by the 5-ht2a receptor, serotonin transporter, and/or dopamine d1/d2 signaling pathways; Treatment of schizophrenia; Treatment of bipolar depression mediated by the...

Dosage: CAPSULE

Strength	Dosage	Availability
EQ 21MG BASE	CAPSULE	Prescription
EQ 42MG BASE	CAPSULE	Prescription
EQ 10.5MG BASE	CAPSULE	Prescription

CAPLYTA family patents

17. Combogesic patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11197830	AFT PHARMS US	Pharmaceutical composition containing acetaminophen and ibuprofen	Feb, 2039 (14 years from now)
US11534407	AFT PHARMS US	Pharmaceutical compostion containing acetominophen and ibuprofen	Feb, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 01, 2026

Drugs and Companies using ACETAMINOPHEN; IBUPROFEN ingredient

Market Authorisation Date: 01 March, 2023

Treatment: A method of treating mild to moderate acute pain in adults by administering 975-1000 mg of acetaminophen and 292.5-300 mg of ibuprofen in a single administration

Dosage: TABLET

COMBOGESIC family patents

18. Cosela patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529352	PHARMACOSMOS	Preservation of immune response during chemotherapy regimens	Jul, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Feb 12, 2026

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

NCE-1 date: 12 February, 2025

Market Authorisation Date: 12 February, 2021

Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen that includes an immune checkpoint inhi...

Dosage: POWDER

COSELA family patents

19. Cuvrior patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10988436	ORPHALAN	Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use	May, 2039 (14 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11072577	ORPHALAN	Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use	May, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Apr 28, 2025
Orphan Drug Exclusivity(ODE-401)	Apr 28, 2029

Drugs and Companies using TRIENTINE TETRAHYDROCHLORIDE ingredient

Market Authorisation Date: 28 April, 2022

Treatment: A method for the treatment of adult patients with stable wilson’s disease who are de-coppered and tolerant to penicillamine

Dosage: TABLET

CUVRIOR family patents

20. Dexycu Kit patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11097061	EYEPOINT PHARMS	Systems, kits and methods for loading and delivering a small volume dose from a syringe	Jun, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Feb 09, 2021

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 09 February, 2018

Treatment: A method of loading medication into a syringe and delivering the medication to a treatment site

Dosage: SUSPENSION

DEXYCU KIT family patents

21. Dhivy patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033521	AVION PHARMS	Levodopa fractionated dose composition and use	Mar, 2039 (14 years from now)
US11819485	AVION PHARMS	Levodopa fractionated dose composition and use	Mar, 2039 (14 years from now)
US11439613	AVION PHARMS	Levodopa fractionated dose composition and use	Mar, 2039 (14 years from now)

Drugs and Companies using CARBIDOPA; LEVODOPA ingredient

Market Authorisation Date: 12 November, 2021

Treatment: Method of treating parkinson's disease by orally administering a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg; Treatment of parkinson's disease, post-encephalitic ...

Dosage: TABLET

DHIVY family patents

22. Elcys patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10912795	EXELA PHARMA	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US10478453	EXELA PHARMA	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US11969439	EXELA PHARMA	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US10905713	EXELA PHARMA	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US10918662	EXELA PHARMA	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US11684636	EXELA PHARMA	Stable, highly pure l-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US10933089	EXELA PHARMA	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US11826383	EXELA PHARMA	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US10653719	EXELA PHARMA	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US11679125	EXELA PHARMA	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US11648262	EXELA PHARMA	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US11510941	EXELA PHARMA	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US10583155	EXELA PHARMA	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US11642370	EXELA PHARMA	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US11510942	EXELA PHARMA	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US10905714	EXELA PHARMA	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)

Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 April, 2019

Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition

Dosage: SOLUTION

ELCYS family patents

23. Elucirem patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10973934	GUERBET	Gadolinium bearing PCTA-based contrast agents	Aug, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 21, 2027

Drugs and Companies using GADOPICLENOL ingredient

NCE-1 date: 21 September, 2026

Market Authorisation Date: 21 September, 2022

Treatment: NA

Dosage: SOLUTION

ELUCIREM family patents

24. Eohilia patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564934	TAKEDA PHARMS USA	Stable corticosteroid compositions	Jan, 2039 (14 years from now)
US11260064	TAKEDA PHARMS USA	Stable corticosteroid compositions	Jan, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Feb 09, 2027
Orphan Drug Exclusivity(ODE-466)	Feb 09, 2031

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 09 February, 2024

Treatment: Treatment of eosinophilic esophagitis

Dosage: SUSPENSION

EOHILIA family patents

25. Epidiolex patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11865102	JAZZ PHARMS RES	Cannabidiol preparations and its uses	Apr, 2039 (14 years from now)
US11207292	JAZZ PHARMS RES	Cannabidiol preparations and its uses	Apr, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jul 31, 2023
New Chemical Entity Exclusivity(NCE)	Sep 28, 2023
Orphan Drug Exclusivity(ODE-216)	Sep 28, 2025
M(M-270)	Oct 20, 2026
Orphan Drug Exclusivity(ODE-326)	Jul 31, 2027
Orphan Drug Exclusivity(ODE-332)	Jul 31, 2027

Drugs and Companies using CANNABIDIOL ingredient

NCE-1 date: 28 September, 2022

Market Authorisation Date: 28 September, 2018

Treatment: Use for the treatment of seizures associated with tuberous sclerosis complex; Use for the treatment of seizures associated with lennox-gastaut syndrome

Dosage: SOLUTION

EPIDIOLEX family patents

26. Erzofri patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11666573	LUYE INNOMIND PHARMA	Dosage regimen of paliperidone palmitate extended-release injectable suspension	Sep, 2039 (14 years from now)

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 26 July, 2024

Treatment: Dosing regimen for the treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants by administering an initial dose of paliperidone palmitat...

Dosage: SUSPENSION, EXTENDED RELEASE

ERZOFRI family patents

27. Farxiga patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11826376	ASTRAZENECA AB	Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same	Jul, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-157)	Mar 11, 2018
New Chemical Entity Exclusivity(NCE)	Jan 08, 2019
M(M-212)	Oct 20, 2020
M(M-238)	Feb 22, 2022
New Indication(I-841)	Oct 18, 2022
New Indication(I-834)	May 05, 2023
New Indication(I-857)	Apr 30, 2024
M(M-298)	May 08, 2026
New Patient Population(NPP)	Jun 12, 2027
Pediatric Exclusivity(PED)	Dec 12, 2027

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 08 January, 2014

Treatment: Reduce the risk of cardiovascular death and hospitalization for heart failure and urgent heart failure visits in adults with heart failure with preserved ejection fraction and without type ii diabetes

Dosage: TABLET

FARXIGA family patents

28. Filsuvez patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11266660	CHIESI	Betulin-containing birch bark extracts and their formulation	Jan, 2039 (14 years from now)
US11083733	CHIESI	Betulin-containing birch bark extracts and their formulation	Jan, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 18, 2028
Orphan Drug Exclusivity(ODE-460)	Dec 18, 2030

Drugs and Companies using BIRCH TRITERPENES ingredient

NCE-1 date: 19 December, 2027

Market Authorisation Date: 18 December, 2023

Treatment: Use of birch triterpenes for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa

Dosage: GEL

FILSUVEZ family patents

29. Focinvez patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11065265	STERISCIENCE	Compositions of fosaprepitant and methods of preparation	Jan, 2039 (14 years from now)
US11065256	STERISCIENCE	Administration and dosage of diaminophenothiazines	Jan, 2039 (14 years from now)
US12042504	STERISCIENCE	Injectable fosaprepitant composition	Jan, 2039 (14 years from now)

Drugs and Companies using FOSAPREPITANT DIMEGLUMINE ingredient

Market Authorisation Date: 22 August, 2023

Treatment: NA

Dosage: SOLUTION

FOCINVEZ family patents

30. Fotivda patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11504365	AVEO PHARMS	Use of tivozanib to treat subjects with refractory cancer	Nov, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 10, 2026

Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient

NCE-1 date: 10 March, 2025

Market Authorisation Date: 10 March, 2021

Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...

Dosage: CAPSULE

FOTIVDA family patents

31. Galafold patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11826360	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	Feb, 2039 (14 years from now)
US11622962	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	Mar, 2039 (14 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11357784	AMICUS THERAP US	Use of migalastat for treating Fabry disease in pregnant patients	Feb, 2039 (14 years from now)
US11642334	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	Feb, 2039 (14 years from now)
US11633388	AMICUS THERAP US	Methods of treating Fabry patients having renal impairment	Mar, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 10, 2023
Orphan Drug Exclusivity(ODE-205)	Aug 10, 2025

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE

GALAFOLD family patents

32. Gavreto patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11963958	RIGEL PHARMS	RET inhibitor for use in treating cancer having a RET alteration	Apr, 2039 (14 years from now)
US11273160	RIGEL PHARMS	RET inhibitor for use in treating cancer having a RET alteration	Apr, 2039 (14 years from now)
US11872192	RIGEL PHARMS	RET inhibitor for use in treating cancer having a RET alteration	Apr, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 04, 2025
Orphan Drug Exclusivity(ODE-318)	Sep 04, 2027
Orphan Drug Exclusivity(ODE-340)	Dec 01, 2027
Orphan Drug Exclusivity(ODE-341)	Dec 01, 2027

Drugs and Companies using PRALSETINIB ingredient

NCE-1 date: 04 September, 2024

Market Authorisation Date: 04 September, 2020

Treatment: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractor...

Dosage: CAPSULE

GAVRETO family patents

33. Igalmi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11478422	BIOXCEL	Film formulations containing dexmedetomidine and methods of producing them	Jun, 2039 (14 years from now)
US11517524	BIOXCEL	Film formulations containing dexmedetomidine and methods of producing them	Jun, 2039 (14 years from now)
US10792246	BIOXCEL	Film formulations containing dexmedetomidine and methods of producing them	Jun, 2039 (14 years from now)
US11497711	BIOXCEL	Film formulations containing dexmedetomidine and methods of producing them	Jun, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Apr 05, 2025

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 April, 2022

Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by buccal administration; Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder ...

Dosage: FILM

IGALMI family patents

34. Ingrezza patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11026931	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Aug, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Apr 11, 2022
New Indication(I-925)	Aug 18, 2026
Orphan Drug Exclusivity(ODE-440)	Aug 18, 2030

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: 11 April, 2021

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia

Dosage: CAPSULE

INGREZZA family patents

35. Ingrezza Sprinkle patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11026931	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Aug, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-925)	Aug 18, 2026

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

Market Authorisation Date: 30 April, 2024

Treatment: Treatment of tardive dyskinesia

Dosage: CAPSULE

INGREZZA SPRINKLE family patents

36. Inrebic patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11400092	BRISTOL-MYERS	Methods of treating myeloproliferative disorders	Sep, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 16, 2024
Orphan Drug Exclusivity(ODE-259)	Aug 16, 2026

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

NCE-1 date: 17 August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring thiamine levels and administering thiamine or a thiamine equivalent

Dosage: CAPSULE

INREBIC family patents

37. Jatenzo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564933	TOLMAR	Methods of treating testosterone deficiency	Apr, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 27, 2022

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 27 March, 2019

Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

Dosage: CAPSULE

JATENZO family patents

38. Katerzia patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799453	AZURITY	Amlodipine formulations	Apr, 2039 (14 years from now)

Drugs and Companies using AMLODIPINE BENZOATE ingredient

Market Authorisation Date: 08 July, 2019

Treatment: NA

Dosage: SUSPENSION

KATERZIA family patents

39. Khapzory patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11541012	ACROTECH BIOPHARMA	Compositions comprising disodium levofolinate	Mar, 2039 (14 years from now)

Drugs and Companies using LEVOLEUCOVORIN ingredient

Market Authorisation Date: 19 October, 2018

Treatment: NA

Dosage: POWDER

KHAPZORY family patents

40. Konvomep patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103492	AZURITY	Compositions and kits for omeprazole suspension	Jul, 2039 (14 years from now)
US10751333	AZURITY	Compositions and kits for omeprazole suspension	Jul, 2039 (14 years from now)
US12042539	AZURITY	Compositions and kits for Omeprazole suspension	Jul, 2039 (14 years from now)
US11633478	AZURITY	Compositions and kits for Omeprazole suspension	Jul, 2039 (14 years from now)
US11911473	AZURITY	Compositions and kits for omeprazole suspension	Jul, 2039 (14 years from now)

Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient

Market Authorisation Date: 30 August, 2022

Treatment: Reduction of risk of upper gastrointestinal bleeding in critically ill patients

Dosage: FOR SUSPENSION

KONVOMEP family patents

41. Likmez patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11541035	SAPTALIS PHARMS	Oral formulations of metronidazole and methods of treating an infection using same	Oct, 2039 (14 years from now)

Drugs and Companies using METRONIDAZOLE ingredient

Market Authorisation Date: 22 September, 2023

Treatment: NA

Dosage: SUSPENSION

LIKMEZ family patents

42. Lumason patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11723869	BRACCO	Freeze-dried product and gas-filled microvesicles suspension	May, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-728)	Mar 31, 2019
New Chemical Entity Exclusivity(NCE)	Oct 10, 2019
New Patient Population(NPP)	Nov 13, 2022

Drugs and Companies using SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES ingredient

NCE-1 date: 10 October, 2018

Market Authorisation Date: 15 October, 2014

Treatment: Use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions

Dosage: FOR SUSPENSION

LUMASON family patents

43. Lutathera patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596278 (Pediatric)	AAA USA INC	Stable, concentrated radionuclide complex solutions	Jan, 2039 (14 years from now)
US11904027 (Pediatric)	AAA USA INC	Stable, concentrated radionuclide complex solutions	Jan, 2039 (14 years from now)
US10596276 (Pediatric)	AAA USA INC	Stable, concentrated radionuclide complex solutions	Jan, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 26, 2023
Orphan Drug Exclusivity(ODE-166)	Jan 26, 2025
New Patient Population(NPP)	Apr 23, 2027
Orphan Drug Exclusivity(ODE-479)	Apr 23, 2031
Pediatric Exclusivity(PED)	Oct 23, 2031

Drugs and Companies using LUTETIUM LU 177 DOTATATE ingredient

NCE-1 date: 23 October, 2030

Market Authorisation Date: 26 January, 2018

Treatment: NA

Dosage: SOLUTION

LUTATHERA family patents

44. Lytgobi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11833151	TAIHO ONCOLOGY	Pharmaceutical composition including sodium alkyl sulfate	Nov, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 30, 2027
Orphan Drug Exclusivity(ODE-410)	Sep 30, 2029

Drugs and Companies using FUTIBATINIB ingredient

NCE-1 date: 30 September, 2026

Market Authorisation Date: 30 September, 2022

Treatment: NA

Dosage: TABLET

LYTGOBI family patents

45. Lyvispah patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792262	AMNEAL	Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives	Jul, 2039 (14 years from now)
US11654124	AMNEAL	Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives	Jul, 2039 (14 years from now)
US11931328	AMNEAL	Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives	Jul, 2039 (14 years from now)

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 22 November, 2021

Treatment: Method for treating spasticity

Dosage: GRANULES

LYVISPAH family patents

46. Metaxalone patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11918559	PRIMUS PHARMS	Reduced dose metaxalone formulations	Jul, 2039 (14 years from now)

Drugs and Companies using METAXALONE ingredient

Market Authorisation Date: 01 June, 2015

Treatment: NA

Dosage: TABLET

METAXALONE family patents

47. Mounjaro patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11357820	ELI LILLY AND CO	GIP/GLP1 agonist compositions	Jun, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 July, 2023

Treatment: NA

Dosage: SOLUTION

MOUNJARO family patents

48. Mounjaro (autoinjector) patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11357820	ELI LILLY AND CO	GIP/GLP1 agonist compositions	Jun, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 July, 2023

Treatment: NA

Dosage: SOLUTION

MOUNJARO (AUTOINJECTOR) family patents

49. Myhibbin patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11931455	AZURITY	Pharmaceutical suspension for oral dosage	Aug, 2039 (14 years from now)
US12097285	AZURITY	Mycophenolate oral suspension	Aug, 2039 (14 years from now)
US12097284	AZURITY	Mycophenolate oral suspension	Aug, 2039 (14 years from now)

Drugs and Companies using MYCOPHENOLATE MOFETIL ingredient

Market Authorisation Date: 01 May, 2024

Treatment: Prophylaxis of organ rejection

Dosage: SUSPENSION

MYHIBBIN family patents

50. Neffy patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11744895	ARS PHARMS OPERATION	Intranasal epinephrine formulations and methods for the treatment of disease	Feb, 2039 (14 years from now)
US11717571	ARS PHARMS OPERATION	Intranasal epinephrine formulations and methods for the treatment of disease	Feb, 2039 (14 years from now)
US11191838	ARS PHARMS OPERATION	Intranasal epinephrine formulations and methods for the treatment of disease	Feb, 2039 (14 years from now)
US10682414	ARS PHARMS OPERATION	Intranasal epinephrine formulations and methods for the treatment of disease	Feb, 2039 (14 years from now)
US11918655	ARS PHARMS OPERATION	Intranasal epinephrine formulations and methods for the treatment of disease	Feb, 2039 (14 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 09 August, 2024

Treatment: Nasal administration of epinephrine for the treatment of allergic reactions (type i), including anaphylaxis

Dosage: SPRAY

NEFFY family patents

51. Norepinephrine Bitartrate In 0.9% Sodium Chloride patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888534	INFORLIFE	Storage stable ready-to-use norepinephrine aqueous solutions in flexible plastic bags	Apr, 2039 (14 years from now)

Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient

Market Authorisation Date: 15 September, 2022

Treatment: NA

Dosage: SOLUTION

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE family patents

52. Nouress patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10933089	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US11679125	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US10478453	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US10653719	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US10583155	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US11684636	BAXTER HLTHCARE CORP	Stable, highly pure l-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US10918662	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US10905714	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US11826383	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US11642370	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US11648262	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US10905713	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US11510942	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US10912795	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (14 years from now)
US11510941	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Mar, 2039 (14 years from now)
US10702490	BAXTER HLTHCARE CORP	Cysteine composition and injection	Mar, 2039 (14 years from now)
US10543186	BAXTER HLTHCARE CORP	Cysteine composition and injection	Mar, 2039 (14 years from now)
US10493051	BAXTER HLTHCARE CORP	Cysteine composition and injection	Mar, 2039 (14 years from now)
US11045438	BAXTER HLTHCARE CORP	Cysteine composition and injection	Mar, 2039 (14 years from now)

Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 December, 2019

Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition; Method of intravenously administering a diluted cysteine hydrochloride solution to a neonate in need ther...

Dosage: SOLUTION

NOURESS family patents

53. Nurtec Odt patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11083724	PFIZER	Rimegepant for CGRP related disorders	Mar, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-865)	May 27, 2024
New Chemical Entity Exclusivity(NCE)	Feb 27, 2025

Drugs and Companies using RIMEGEPANT SULFATE ingredient

NCE-1 date: 28 February, 2024

Market Authorisation Date: 27 February, 2020

Treatment: Preventive treatment of episodic migraine in adults

Dosage: TABLET, ORALLY DISINTEGRATING

NURTEC ODT family patents

54. Ogsiveo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11845732	SPRINGWORKS	Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof	Aug, 2039 (14 years from now)
US10941118	SPRINGWORKS	Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof	Aug, 2039 (14 years from now)
US10710966	SPRINGWORKS	Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof	Aug, 2039 (14 years from now)
US10590087	SPRINGWORKS	Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof	Aug, 2039 (14 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11820748	SPRINGWORKS	Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof	Aug, 2039 (14 years from now)
US11884635	SPRINGWORKS	Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof	Aug, 2039 (14 years from now)
US11884634	SPRINGWORKS	Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide	Aug, 2039 (14 years from now)
US11905255	SPRINGWORKS	Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof	Aug, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Nov 27, 2028
ODE(ODE)	Nov 27, 2030
Orphan Drug Exclusivity(ODE-452)	Nov 27, 2030

Drugs and Companies using NIROGACESTAT HYDROBROMIDE ingredient

NCE-1 date: 28 November, 2027

Market Authorisation Date: 27 November, 2023

Treatment: Treatment of adult patients with progressing desmoid tumors

Dosage: TABLET

OGSIVEO family patents

55. Omlonti patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11666563	VISIOX PHARMA	Pharmaceutical preparation containing pyridyl aminoacetic acid compound	Jul, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

NCE-1 date: 22 September, 2026

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION

OMLONTI family patents

56. Oriahnn (copackaged) patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11542239	ABBVIE	Elagolix sodium compositions and processes	Jul, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 29, 2023
New Chemical Entity Exclusivity(NCE)	Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

NCE-1 date: 23 July, 2022

Market Authorisation Date: 29 May, 2020

Treatment: NA

Dosage: CAPSULE

ORIAHNN (COPACKAGED) family patents

57. Orilissa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11542239	ABBVIE	Elagolix sodium compositions and processes	Jul, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: 23 July, 2022

Market Authorisation Date: 23 July, 2018

Treatment: NA

Dosage: TABLET

ORILISSA family patents

58. Orladeyo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10662160	BIOCRYST	Crystalline salts of a plasma kallikrein inhibitor	Nov, 2039 (14 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11618733	BIOCRYST	Crystalline salts of a plasma kallikrein inhibitor	Nov, 2039 (14 years from now)
US11117867	BIOCRYST	Crystalline salts of a plasma kallikrein inhibitor	Nov, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 03, 2025
Orphan Drug Exclusivity(ODE-333)	Dec 03, 2027

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

NCE-1 date: 03 December, 2024

Market Authorisation Date: 03 December, 2020

Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older

Dosage: CAPSULE

ORLADEYO family patents

59. Ozobax patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610502	METACEL PHARMS LLC	Oral baclofen solutions	Aug, 2039 (14 years from now)

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 18 September, 2019

Treatment: Treatment of spasticity

Dosage: SOLUTION

OZOBAX family patents

60. Pedmark patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11964018	FENNEC PHARMS INC	Therapeutic uses for sodium thiosulfate formulations	Jul, 2039 (14 years from now)
US11617793	FENNEC PHARMS INC	Anhydrous sodium thiosulfate and formulations thereof	Jul, 2039 (14 years from now)
US11291728	FENNEC PHARMS INC	Anhydrous sodium thiosulfate and formulations thereof	Jul, 2039 (14 years from now)
US11998604	FENNEC PHARMS INC	Therapeutic uses for sodium thiosulfate formulations	Jul, 2039 (14 years from now)
US11992530	FENNEC PHARMS INC	Therapeutic uses for sodium thiosulfate and formulations	Jul, 2039 (14 years from now)
US11510984	FENNEC PHARMS INC	Anhydrous sodium thiosulfate and formulations thereof	Jul, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Sep 20, 2025
Orphan Drug Exclusivity(ODE-384)	Sep 20, 2029

Drugs and Companies using SODIUM THIOSULFATE ingredient

Market Authorisation Date: 20 September, 2022

Treatment: Use of a pharmaceutical composition of about 0.5m sodium thiosulfate, about 0.004m boric acid, and a ph of between about 6.5 and 8.9 for reducing ototoxicity in a pediatric patient receiving cisplatin...

Dosage: SOLUTION

PEDMARK family patents

61. Pemazyre patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11466004	INCYTE CORP	Solid forms of an FGFR inhibitor and processes for preparing the same	May, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Apr 17, 2025
New Indication(I-899)	Aug 26, 2025
Orphan Drug Exclusivity(ODE-292)	Apr 17, 2027
Orphan Drug Exclusivity(ODE-404)	Aug 26, 2029

Drugs and Companies using PEMIGATINIB ingredient

NCE-1 date: 17 April, 2024

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib in a daily dose of about 5 mg to...

Dosage: TABLET

PEMAZYRE family patents

62. Potassium Phosphates patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10632150	CMP DEV LLC	Potassium phosphates composition for injection	Apr, 2039 (14 years from now)

Drugs and Companies using POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC ingredient

Market Authorisation Date: 19 September, 2019

Treatment: Potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older

Dosage: SOLUTION

POTASSIUM PHOSPHATES family patents

63. Proair Digihaler patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11344685	TEVA BRANDED PHARM	Drug delivery device with electronics	Sep, 2039 (14 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER, METERED

PROAIR DIGIHALER family patents

64. Qvar Redihaler patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792447	NORTON WATERFORD	Breath actuated inhaler	Jan, 2039 (14 years from now)
US11559637	NORTON WATERFORD	Inhalers and related methods	Jul, 2039 (14 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 03 August, 2017

Treatment: NA

Dosage: AEROSOL, METERED

QVAR REDIHALER family patents

65. Radicava Ors patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11957660	MITSUBISHI TANABE	Edaravone suspension for oral administration	Nov, 2039 (14 years from now)
US11826352	MITSUBISHI TANABE	Edaravone suspension for oral administration	Nov, 2039 (14 years from now)
US10987341	MITSUBISHI TANABE	Edaravone suspension for oral administration	Nov, 2039 (14 years from now)
US11478450	MITSUBISHI TANABE	Edaravone suspension for oral administration	Nov, 2039 (14 years from now)
US11241416	MITSUBISHI TANABE	Edaravone suspension for oral administration	Nov, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 12, 2025
Orphan Drug Exclusivity(ODE-144)	May 12, 2029

Drugs and Companies using EDARAVONE ingredient

Market Authorisation Date: 12 May, 2022

Treatment: Treatment of amyotrophic lateral sclerosis

Dosage: SUSPENSION

RADICAVA ORS family patents

66. Rezlidhia patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10532047	RIGEL PHARMS	Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile	May, 2039 (14 years from now)
US12053463	RIGEL PHARMS	Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile	May, 2039 (14 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11013733	RIGEL PHARMS	Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)	May, 2039 (14 years from now)
US11013734	RIGEL PHARMS	Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation	May, 2039 (14 years from now)
US11376246	RIGEL PHARMS	Inhibiting mutant IDH-1	May, 2039 (14 years from now)
US11497743	RIGEL PHARMS	Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation	May, 2039 (14 years from now)
US10959994	RIGEL PHARMS	Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile	May, 2039 (14 years from now)
US11738018	RIGEL PHARMS	Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)	Jul, 2039 (14 years from now)
US11723905	RIGEL PHARMS	Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile	Nov, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 01, 2027
Orphan Drug Exclusivity(ODE-413)	Dec 01, 2029

Drugs and Companies using OLUTASIDENIB ingredient

NCE-1 date: 01 December, 2026

Market Authorisation Date: 01 December, 2022

Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer is acute myeloid leukemia (aml); A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehyd...

Dosage: CAPSULE

REZLIDHIA family patents

67. Ryzumvi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11400077	FAMYGEN LIFE SCI	Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders	Oct, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Sep 25, 2026

Drugs and Companies using PHENTOLAMINE MESYLATE ingredient

Market Authorisation Date: 25 September, 2023

Treatment: Treatment of pharmacologically-induced mydriasis

Dosage: SOLUTION

RYZUMVI family patents

68. Sotalol Hydrochloride patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799138	ALTATHERA PHARMS LLC	Method of administering sotalol IV/switch	Apr, 2039 (14 years from now)
US11583216	ALTATHERA PHARMS LLC	Method of administering sotalol IV/switch	Aug, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE)	Jul 02, 2016

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Market Authorisation Date: 02 July, 2009

Treatment: Use for loading dose in patients with symptomatic afib/afl who are currently in sinus rhythm or for the treatment of life-threatening ventricular tachycardia; Intravenous sotalol dosing regimen for us...

Dosage: SOLUTION

SOTALOL HYDROCHLORIDE family patents

69. Spy Agent Green Kit patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11712320	NOVADAQ TECH	Methods and systems to automate surgical interventions	Jul, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Nov 21, 2021
New Indication(I-911)	Jun 05, 2026

Drugs and Companies using INDOCYANINE GREEN ingredient

Market Authorisation Date: 21 November, 2018

Treatment: NA

Dosage: POWDER

SPY AGENT GREEN KIT family patents

70. Sunosi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11560354	AXSOME MALTA	Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof	Mar, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 17, 2024
Orphan Drug Exclusivity(ODE-254)	Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 18 June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness by administering a composition comprising solriamfetol hydrochloride and 2-chloropropane, wherein the composition comprises less than about 5 ppm 2‑chloroprop...

Dosage: TABLET

SUNOSI family patents

71. Tavneos patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11951214	CHEMOCENTRYX	Capsule formulations	Nov, 2039 (15 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 07, 2026
Orphan Drug Exclusivity(ODE-377)	Oct 07, 2028

Drugs and Companies using AVACOPAN ingredient

NCE-1 date: 07 October, 2025

Market Authorisation Date: 07 October, 2021

Treatment: NA

Dosage: CAPSULE

TAVNEOS family patents

72. Testosterone Cypionate patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11642355	AZURITY	Pharmaceutical compositions of testosterone	Mar, 2039 (14 years from now)
US11311554	AZURITY	Pharmaceutical compositions of testosterone	Mar, 2039 (14 years from now)

Drugs and Companies using TESTOSTERONE CYPIONATE ingredient

Market Authorisation Date: 02 June, 2022

Treatment: NA

Dosage: SOLUTION

TESTOSTERONE CYPIONATE family patents

73. Tibsovo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10980788	SERVIER	Therapy for treating malignancies	Jun, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-816)	May 02, 2022
New Chemical Entity Exclusivity(NCE)	Jul 20, 2023
New Indication(I-875)	Aug 25, 2024
New Indication(I-893)	May 25, 2025
Orphan Drug Exclusivity(ODE-203)	Jul 20, 2025
Orphan Drug Exclusivity(ODE-242)	May 02, 2026
New Indication(I-924)	Oct 24, 2026
Orphan Drug Exclusivity(ODE-368)	Aug 25, 2028
Orphan Drug Exclusivity(ODE-447)	Oct 24, 2030

Drugs and Companies using IVOSIDENIB ingredient

NCE-1 date: 20 July, 2022

Market Authorisation Date: 20 July, 2018

Treatment: Treating relapsed/refractory acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested...

Dosage: TABLET

TIBSOVO family patents

74. Tirosint-sol patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11241382	IBSA	Administration regimen of compositions of T4 thyroid hormone with high oral absorption	Sep, 2039 (14 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 15 December, 2016

Treatment: Treatment of pituitary thyrotropin suppression by oral administration of l-thyroxine to a patient on an empty stomach 15 minutes before breakfast

Dosage: SOLUTION

TIROSINT-SOL family patents

75. Trudhesa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11185497	IMPEL PHARMS	Intranasal delivery of dihydroergotamine by precision olfactory device	Jan, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Sep 02, 2024

Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient

Market Authorisation Date: 02 September, 2021

Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura

Dosage: SPRAY, METERED

TRUDHESA family patents

76. Upneeq patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10814001	RVL PHARMS	Oxymetazoline compositions	Dec, 2039 (15 years from now)
US10898573	RVL PHARMS	Oxymetazoline compositions	Dec, 2039 (15 years from now)
US11103482	RVL PHARMS	Oxymetazoline compositions	Dec, 2039 (15 years from now)
US11541036	RVL PHARMS	Oxymetazoline compositions	Dec, 2039 (15 years from now)
US10940138	RVL PHARMS	Compositions and methods for treating ocular disorders	Dec, 2039 (15 years from now)
US11324722	RVL PHARMS	Compositions and methods for treating ocular disorders	Dec, 2039 (15 years from now)
US11701343	RVL PHARMS	Compositions and methods for treating ocular disorders	Dec, 2039 (15 years from now)
US10799481	RVL PHARMS	Compositions and methods for treating ocular disorders	Dec, 2039 (15 years from now)
US11311515	RVL PHARMS	Oxymetazoline compositions	Dec, 2039 (15 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jul 08, 2023

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 July, 2020

Treatment: Method of treating blepharoptosis

Dosage: SOLUTION/DROPS

UPNEEQ family patents

77. Vabomere patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11376237	REMPEX	Methods of treating bacterial infections	Apr, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 29, 2022
Generating Antibiotic Incentives Now(GAIN)	Aug 29, 2027

Drugs and Companies using MEROPENEM; VABORBACTAM ingredient

NCE-1 date: 29 August, 2026

Market Authorisation Date: 29 August, 2017

Treatment: Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli,klebsiella pneumonia,enterobacter cloacae species...

Dosage: POWDER

VABOMERE family patents

78. Veklury patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11266681 (Pediatric)	GILEAD SCIENCES INC	Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections	Jan, 2039 (14 years from now)
US10675296 (Pediatric)	GILEAD SCIENCES INC	Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections	Jan, 2039 (14 years from now)
US11975017 (Pediatric)	GILEAD SCIENCES INC	Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections	Jan, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosing Schedule(D-183)	Jan 21, 2025
New Patient Population(NPP)	Apr 25, 2025
New Chemical Entity Exclusivity(NCE)	Oct 22, 2025
M(M-301)	Jul 13, 2026
Pediatric Exclusivity(PED)	Jan 13, 2027

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: 13 January, 2026

Market Authorisation Date: 22 October, 2020

Treatment: NA

Dosage: SOLUTION; POWDER

VEKLURY family patents

79. Vevye patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11413323	HARROW EYE	Ophthalmic composition for treatment of dry eye disease	Oct, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 30, 2026

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 30 May, 2023

Treatment: Treatment of dry eye disease (ded)

Dosage: SOLUTION

VEVYE family patents

80. Vigafyde patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12016857	PYROS PHARMS	Stable liquid vigabatrin pharmaceutical composition for oral dosage	Aug, 2039 (14 years from now)

Drugs and Companies using VIGABATRIN ingredient

Market Authorisation Date: 17 June, 2024

Treatment: NA

Dosage: SOLUTION

VIGAFYDE family patents

81. Voranigo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11345677	SERVIER	Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same	Jan, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 06, 2029
Orphan Drug Exclusivity(ODE-491)	Aug 06, 2031

Drugs and Companies using VORASIDENIB ingredient

NCE-1 date: 06 August, 2028

Market Authorisation Date: 06 August, 2024

Treatment: A method of treating a cancer characterized by an idh1 or idh2 mutation or combination thereof following surgery, wherein the cancer is grade 2 astrocytoma or oligodendroglioma

Dosage: TABLET

VORANIGO family patents

82. Vtama patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590088	DERMAVANT SCI	Use of Tapinarof for the treatment of chronic plaque psoriasis	Nov, 2039 (15 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 23, 2027

Drugs and Companies using TAPINAROF ingredient

NCE-1 date: 23 May, 2026

Market Authorisation Date: 23 May, 2022

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: CREAM

VTAMA family patents

83. Vuity patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11285134	ABBVIE	Presbyopia treatments	Apr, 2039 (14 years from now)
US10610518	ABBVIE	Presbyopia treatments	Apr, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Oct 28, 2024
New Dosing Schedule(D-187)	Mar 28, 2026

Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 October, 2021

Treatment: Use of vuity for the treatment of presbyopia in adults

Dosage: SOLUTION

VUITY family patents

84. Wynzora patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11638711	MC2	NULL	Mar, 2039 (14 years from now)
US11696919	MC2	Topical composition	Mar, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Jul 20, 2023

Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient

Market Authorisation Date: 20 July, 2020

Treatment: NA

Dosage: CREAM

WYNZORA family patents

85. Xarelto patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10828310	JANSSEN PHARMS	Reducing the risk of cardiovascular events	Jan, 2039 (14 years from now)
US10828310 (Pediatric)	JANSSEN PHARMS	Reducing the risk of cardiovascular events	Jul, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-643)	Nov 04, 2014
New Indication(I-660)	Nov 02, 2015
New Indication(I-661)	Nov 02, 2015
New Indication(I-662)	Nov 02, 2015
New Chemical Entity Exclusivity(NCE)	Jul 01, 2016
New Dosing Schedule(D-168)	Oct 27, 2020
New Indication(I-824)	Oct 11, 2021
New Indication(I-810)	Oct 11, 2022
M(M-284)	Mar 10, 2023
New Indication(I-867)	Aug 23, 2024
New Product(NP)	Dec 20, 2024
Pediatric Exclusivity(PED)	Jun 20, 2025

Drugs and Companies using RIVAROXABAN ingredient

NCE-1 date: 24 February, 2024

Market Authorisation Date: 11 October, 2018

Treatment: Reduction of risk of myocardial infarction and ischemic stroke in patients with pad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin d...

Dosage: TABLET

XARELTO family patents

86. Xcopri patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11654133	SK LIFE	Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy	Jun, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 10, 2025

Drugs and Companies using CENOBAMATE ingredient

NCE-1 date: 10 March, 2024

Market Authorisation Date: 10 March, 2020

Treatment: Co-administration of cenobamate with phenobarbital and/or phenytoin for the treatment of partial onset seizures

Dosage: TABLET

XCOPRI family patents

87. Xofluza patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12064438	GENENTECH INC	Pharmaceutical preparation excellent in light stability and dissolution property	Oct, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-811)	Oct 16, 2022
New Chemical Entity Exclusivity(NCE)	Oct 24, 2023

Drugs and Companies using BALOXAVIR MARBOXIL ingredient

NCE-1 date: 24 October, 2022

Market Authorisation Date: 24 October, 2018

Treatment: NA

Dosage: TABLET

XOFLUZA family patents

88. Yupelri patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12048692	MYLAN IRELAND LTD	Methods for treating chronic obstructive pulmonary disease	Aug, 2039 (14 years from now)
US11484531	MYLAN IRELAND LTD	Methods for treating chronic obstructive pulmonary disease	Oct, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Nov 09, 2023

Drugs and Companies using REVEFENACIN ingredient

NCE-1 date: 09 November, 2022

Market Authorisation Date: 09 November, 2018

Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION

YUPELRI family patents

89. Zejula patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11730725	GLAXOSMITHKLINE	Niraparib formulations	Jan, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 27, 2022
New Indication(I-813)	Oct 23, 2022
New Indication(I-814)	Oct 23, 2022
New Indication(I-833)	Apr 29, 2023
Orphan Drug Exclusivity(ODE)	Mar 27, 2024
Orphan Drug Exclusivity(ODE-133)	Mar 27, 2024
Orphan Drug Exclusivity(ODE-277)	Oct 23, 2026
Orphan Drug Exclusivity(ODE-278)	Oct 23, 2026
Orphan Drug Exclusivity(ODE-295)	Apr 29, 2027

Drugs and Companies using NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 26 April, 2023

Treatment: NA

Dosage: TABLET

ZEJULA family patents

90. Zepbound patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11357820	ELI LILLY AND CO	GIP/GLP1 agonist compositions	Jun, 2039 (14 years from now)
US11918623	ELI LILLY AND CO	GIP/GLP1 agonist compositions	Jun, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 13, 2027
M(M-82)	Oct 18, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 March, 2024

Treatment: For chronic weight management in adults with an initial body mass index (bmi) of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related como...

Dosage: SOLUTION

ZEPBOUND family patents

91. Zepbound (autoinjector) patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11918623	ELI LILLY AND CO	GIP/GLP1 agonist compositions	Jun, 2039 (14 years from now)
US11357820	ELI LILLY AND CO	GIP/GLP1 agonist compositions	Jun, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Nov 08, 2026
New Chemical Entity Exclusivity(NCE)	May 13, 2027
M(M-82)	Oct 18, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 March, 2024

Dosage: SOLUTION

ZEPBOUND (AUTOINJECTOR) family patents

92. Zimhi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11027072	ZMI PHARMA	Emergency devices	May, 2039 (14 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2021

Treatment: NA

Dosage: SOLUTION

ZIMHI family patents

93. Zurnai (autoinjector) patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11865112	PURDUE PHARMA LP	Compositions and methods for opioid antagonist delivery	Nov, 2039 (14 years from now)
US11857547	PURDUE PHARMA LP	Compositions and methods for opioid antagonist delivery	Nov, 2039 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Aug 07, 2027

Drugs and Companies using NALMEFENE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 August, 2024

Treatment: Treating opioid overdose

Dosage: SOLUTION

ZURNAI (AUTOINJECTOR) family patents

List of large molecules

1. List of Eylea large molecules

Patent Number	Company	Patent Title	Patent Expiry
US11103552	REGENERON PHARMACEUTICALS, INC.	High concentration VEGF receptor fusion protein containing formulations	May, 2039 (14 years from now)
US10973879	REGENERON PHARMACEUTICALS, INC.	Use of a VEGF antagonist to treat angiogenic eye disorders	May, 2039 (14 years from now)
US11160918	REGENERON PHARMACEUTICALS, INC.	Medical device packaging and related methods	Jul, 2039 (14 years from now)
US11850407	REGENERON PHARMACEUTICALS, INC.	Needle shield grip devices and related methods	Sep, 2039 (14 years from now)

Ingredients: AFLIBERCEPT

2. List of Stelara large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US10961307	JANSSEN BIOTECH, INC.	Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody	Sep, 2039 (14 years from now)

Ingredients: USTEKINUMAB

3. List of Prolia And Xgeva large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US11744950	AMGEN INC.	Controlled dispense syringe	Nov, 2039 (15 years from now)

Ingredients: DENOSUMAB

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US11642370	February, 2024	Institution Denied	Exela Pharma Sciences, LLC	Nexus Pharmaceuticals LLC
US10653719	September, 2020	Institution Denied	Exela Pharma Sciences LLC	Eton Pharmaceuticals, Inc.
US10583155	June, 2020	Terminated-Denied	Exela Pharma Sciences, LLC	Eton Pharmaceuticals Inc.
US10478453	May, 2020	Institution Denied	Exela Pharma Sciences, LLC	Eton Pharmaceuticals, Inc.

Application	Filing Date	Opposition Party	Legal Status

EP19753296A	2021-08-02	COHAUSZ & FLORACK Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB	Granted and Under Opposition

Strength	Dosage	Availability
7.2765GM/15ML (485.1MG/ML)	SOLUTION	Prescription
3.63825GM/7.5ML (485.1MG/ML)	SOLUTION	Prescription
4.851GM/10ML (485.1MG/ML)	SOLUTION	Prescription
24.255GM/50ML (485.1MG/ML)	SOLUTION	Prescription
1.4553GM/3ML (485.1MG/ML)	SOLUTION	Prescription
48.51GM/100ML (485.1MG/ML)	SOLUTION	Prescription
14.553GM/30ML (485.1MG/ML)	SOLUTION	Prescription

Strength	Dosage	Availability
117MG/0.75ML (117MG/0.75ML)	SUSPENSION, EXTENDED RELEASE	Prescription
156MG/ML (156MG/ML)	SUSPENSION, EXTENDED RELEASE	Prescription
234MG/1.5ML (156MG/ML)	SUSPENSION, EXTENDED RELEASE	Prescription
351MG/2.25ML (156MG/ML)	SUSPENSION, EXTENDED RELEASE	Prescription
78MG/0.5ML (78MG/0.5ML)	SUSPENSION, EXTENDED RELEASE	Prescription
39MG/0.25ML (39MG/0.25ML)	SUSPENSION, EXTENDED RELEASE	Prescription

Strength	Dosage	Availability
EQ 0.89MG BASE	CAPSULE	Prescription
EQ 1.34MG BASE	CAPSULE	Prescription

Strength	Dosage	Availability
EQ 0.18MG BASE	FILM	Prescription
EQ 0.12MG BASE	FILM	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
40 mg and 80 mg	12 Apr, 2021	4		10 Aug, 2040
60 mg	14 Feb, 2022	1		10 Aug, 2040

Strength	Dosage	Availability
EQ 80MG BASE	CAPSULE	Prescription
EQ 60MG BASE	CAPSULE	Prescription
EQ 40MG BASE	CAPSULE	Prescription

Strength	Dosage	Availability
158MG	CAPSULE	Prescription
237MG	CAPSULE	Prescription
198MG	CAPSULE	Prescription

Strength	Dosage	Availability
5MG/PACKET	GRANULES	Prescription
10MG/PACKET	GRANULES	Prescription
20MG/PACKET	GRANULES	Prescription

Strength	Dosage	Availability
7.5MG/0.5ML (7.5MG/0.5ML)	SOLUTION	Prescription
5MG/0.5ML (5MG/0.5ML)	SOLUTION	Prescription
2.5MG/0.5ML (2.5MG/0.5ML)	SOLUTION	Prescription
12.5MG/0.5ML (12.5MG/0.5ML)	SOLUTION	Prescription
10MG/0.5ML (10MG/0.5ML)	SOLUTION	Prescription
15MG/0.5ML (15MG/0.5ML)	SOLUTION	Prescription

Strength	Dosage	Availability
EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	SOLUTION	Prescription
EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	SOLUTION	Prescription
EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	SOLUTION	Prescription

Strength	Dosage	Availability
EQ 200MG BASE	TABLET	Prescription
EQ 150MG BASE	TABLET	Prescription

Strength	Dosage	Availability
EQ 110MG BASE	CAPSULE	Prescription
EQ 150MG BASE	CAPSULE	Prescription

Strength	Dosage	Availability
4.5MG	TABLET	Prescription
9MG	TABLET	Prescription
13.5MG	TABLET	Prescription

Strength	Dosage	Availability
0.04MG/INH	AEROSOL, METERED	Prescription
0.08MG/INH	AEROSOL, METERED	Prescription

Strength	Dosage	Availability
44MCG/ML	SOLUTION	Prescription
25MCG/ML	SOLUTION	Prescription
50MCG/ML	SOLUTION	Prescription
75MCG/ML	SOLUTION	Prescription
88MCG/ML	SOLUTION	Prescription
100MCG/ML	SOLUTION	Prescription
112MCG/ML	SOLUTION	Prescription
125MCG/ML	SOLUTION	Prescription
137MCG/ML	SOLUTION	Prescription
150MCG/ML	SOLUTION	Prescription
175MCG/ML	SOLUTION	Prescription
200MCG/ML	SOLUTION	Prescription
37.5MCG/ML	SOLUTION	Prescription
62.5MCG/ML	SOLUTION	Prescription
13MCG/ML	SOLUTION	Prescription

Strength	Dosage	Availability
100MG/20ML (5MG/ML)	SOLUTION	Prescription
100MG/VIAL	POWDER	Prescription

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US11590088	April, 2024	Pending	Dermavant Sciences GmbH et al.	Encube Ethicals Pvt. Ltd.

Application	Filing Date	Opposition Party	Legal Status

EP19729883A	2022-12-20	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10828310	February, 2022	Final Written Decision - Appealed	Bayer Pharma AG et al.	Mylan Pharmaceuticals Inc. et al.
US10828310	September, 2022	Final Written Decision	Bayer Pharma AG et al.	InvaGen Pharmaceuticals, Inc. et al.
US10828310	September, 2022	Final Written Decision	Bayer Pharma AG et al.	Teva Pharmaceuticals USA, Inc

Pharsight

Pharsight

Drug Patents Expiring in 2039

1. Adrenalin patent expiration

ADRENALIN family patents

2. Airduo Digihaler patent expiration

AIRDUO DIGIHALER family patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years. Get the exclusive patent insights now. Don't be the last to know. Download Report 3. Airduo Respiclick patent expiration

AIRDUO RESPICLICK family patents

4. Angiomax Rtu patent expiration

ANGIOMAX RTU family patents

5. Anjeso patent expiration

ANJESO family patents

6. Annovera patent expiration

ANNOVERA family patents

7. Aristada patent expiration

ARISTADA family patents

8. Aristada Initio Kit patent expiration

ARISTADA INITIO KIT family patents

9. Armonair Digihaler patent expiration

ARMONAIR DIGIHALER family patents

10. Armonair Respiclick patent expiration

ARMONAIR RESPICLICK family patents

11. Baqsimi patent expiration

BAQSIMI family patents

12. Brexafemme patent expiration

BREXAFEMME family patents

13. Brukinsa patent expiration

BRUKINSA family patents

14. Bylvay patent expiration

BYLVAY family patents

15. Camcevi Kit patent expiration

CAMCEVI KIT family patents

16. Caplyta patent expiration

CAPLYTA family patents

17. Combogesic patent expiration

COMBOGESIC family patents

18. Cosela patent expiration

COSELA family patents

19. Cuvrior patent expiration

CUVRIOR family patents

20. Dexycu Kit patent expiration

DEXYCU KIT family patents

21. Dhivy patent expiration

DHIVY family patents

22. Elcys patent expiration

ELCYS family patents

23. Elucirem patent expiration

ELUCIREM family patents

24. Eohilia patent expiration

EOHILIA family patents

25. Epidiolex patent expiration

EPIDIOLEX family patents

26. Erzofri patent expiration

ERZOFRI family patents

27. Farxiga patent expiration

FARXIGA family patents

28. Filsuvez patent expiration

FILSUVEZ family patents

29. Focinvez patent expiration

FOCINVEZ family patents

30. Fotivda patent expiration

FOTIVDA family patents

31. Galafold patent expiration

GALAFOLD family patents

32. Gavreto patent expiration

GAVRETO family patents

33. Igalmi patent expiration

IGALMI family patents

34. Ingrezza patent expiration

INGREZZA family patents

35. Ingrezza Sprinkle patent expiration

INGREZZA SPRINKLE family patents

36. Inrebic patent expiration

INREBIC family patents

37. Jatenzo patent expiration

JATENZO family patents

38. Katerzia patent expiration

KATERZIA family patents

39. Khapzory patent expiration

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Airduo Respiclick patent expiration

Strength	Submission Date	ANDA(s) Filed	Last patent expiry
2.5 mg	19 Nov, 2018	4	13 Nov, 2024
10 mg, 15 mg, and 20 mg	01 Jul, 2015	8	28 Aug, 2024
10 mg, 15 mg and 20 mg	17 Jun, 2022	1	17 Feb, 2034

Strength	Dosage	Availability
25MG	TABLET	Prescription
50MG	TABLET	Prescription
200MG	TABLET	Prescription
100MG	TABLET	Prescription
12.5MG	TABLET	Prescription
150MG	TABLET	Prescription

Strength	Dosage	Availability
20MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET	Discontinued
80MG	TABLET	Prescription
40MG	TABLET	Prescription